Cargando…

Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C

Combination treatment of ledipasvir and sofosbuvir (LDV/SOF) is first‐line treatment for patients with chronic hepatitis C genotype 1 in the United States, Europe, and Japan. However, the influence of LDV/SOF on the cardiovascular system is poorly characterized. A total of 470 chronic hepatitis C pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tahata, Yuki, Sakamori, Ryotaro, Urabe, Ayako, Morishita, Naoki, Yamada, Ryoko, Yakushijin, Takayuki, Hiramatsu, Naoki, Doi, Yoshinori, Kaneko, Akira, Hagiwara, Hideki, Yamada, Yukinori, Hijioka, Taizo, Inada, Masami, Tamura, Shinji, Imai, Yasuharu, Furuta, Kunimaro, Kodama, Takahiro, Hikita, Hayato, Tatsumi, Tomohide, Takehara, Tetsuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078212/ https://www.ncbi.nlm.nih.gov/pubmed/30094400 http://dx.doi.org/10.1002/hep4.1206

Ejemplares similares

Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis
por: Sakamori, Ryotaro, et al.
Publicado: (2021)

Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral
por: Matsumae, Takayuki, et al.
Publicado: (2023)

Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection
por: Morishita, Naoki, et al.
Publicado: (2020)

Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
por: Maesaka, Kazuki, et al.
Publicado: (2023)

CEACAM1 Is Associated With the Suppression of Natural Killer Cell Function in Patients With Chronic Hepatitis C
por: Suda, Takahiro, et al.
Publicado: (2018)

Hepatocellular Carcinoma in a Patient with Tetralogy of Fallot: A Case Report and Literature Review
por: Hyun Sung, Ji, et al.
Publicado: (2021)

Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment
por: Kai, Yugo, et al.
Publicado: (2017)

White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice
por: Sakane, Sadatsugu, et al.
Publicado: (2021)

Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy
por: Myojin, Yuta, et al.
Publicado: (2022)

The First Case of Coil Embolization for Left Gastric Vein Aneurysm with Liver Cirrhosis: A Case Report and Review of the Literature
por: Kato, Seiya, et al.
Publicado: (2021)

CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma
por: Suemura, Shigeki, et al.
Publicado: (2019)

Real‐world safety and efficacy of sofosbuvir and ledipasvir for elderly patients
por: Tamai, Hideyuki, et al.
Publicado: (2018)

Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients
por: Shirai, Kumiko, et al.
Publicado: (2022)

Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C
por: Tawara, Seiichi, et al.
Publicado: (2016)

Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis
por: Shirai, Kumiko, et al.
Publicado: (2022)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis
por: Kozumi, Kazuhiro, et al.
Publicado: (2021)

Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct‐acting antiviral agents among the working population in Japan
por: Hagiwara, Hideki, et al.
Publicado: (2022)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
por: Premji, Resmi, et al.
Publicado: (2015)

Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir
por: Shenk, Mary Elizabeth Reed, et al.
Publicado: (2018)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy
por: Matsumae, Takayuki, et al.
Publicado: (2022)

Inhibition of nonhomologous end joining‐mediated DNA repair enhances anti‐HBV CRISPR therapy
por: Murai, Kazuhiro, et al.
Publicado: (2022)

Forkhead Box M1 Transcription Factor Drives Liver Inflammation Linking to Hepatocarcinogenesis in Mice
por: Kurahashi, Tomohide, et al.
Publicado: (2019)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

The Hepatitis B Virus Genotype Affects the Persistence of Viral Replication in Immunodeficient NOG Mice
por: Yokoyama, Yoshinobu, et al.
Publicado: (2015)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2018)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
por: Ansari, Umer, et al.
Publicado: (2017)

Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017)

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018)

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir
por: Omotani, Sachiko, et al.
Publicado: (2020)

Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver
por: Urabe, Makiko, et al.
Publicado: (2021)

Increased Bcl-xL Expression in Pancreatic Neoplasia Promotes Carcinogenesis by Inhibiting Senescence and Apoptosis
por: Ikezawa, Kenji, et al.
Publicado: (2017)

Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
por: O'Brien, Thomas R., et al.
Publicado: (2014)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
por: Sundaram, Vinay, et al.
Publicado: (2016)

Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment
por: Golden‐Mason, Lucy, et al.
Publicado: (2018)

Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population
por: Stewart, Rachel A., et al.
Publicado: (2018)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
por: Naylor, Paul H, et al.
Publicado: (2017)

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C
por: Saab, Sammy, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b6pf9b91cbcgnpq3sbfkvd9fr6